Introduction
The liver is a major target of human immunodeficiency virus (HIV) infection and a wide spectrum of liver disease can be seen in patients with HIV infection, ranging from steatosis, steatohepatitis, cirrhosis, non-cirrhotic portal hypertension and hepatocellular carcinoma (1) . HIV infection adversely impacts on the progression of liver diseases. For example, HIV/hepatitis B virus (HBV) co-infected patients had significantly decreased rate of hepatitis B surface antigen (HBsAg) clearance and increased HBV replication than HBV monoinfected individuals (2) (3) , and HIV/hepatitis C virus (HCV) coinfected patients had lower rate of HCV viral suppression than HCV monoinfected controls (4) . Consequently, progression to cirrhosis is more rapid in HIV-infected patients with chronic liver diseases (5) (6) . End stage liver disease (ESLD) has become a major cause of mortality in HIV-infected individuals receiving antiretroviral therapy (ART), accounting for a greater proportion of deaths than cardiovascular disease or non-acquired immune deficiency syndrome (AIDS)-related cancers (7) (8) .
In China, common risk factors for liver disease such as alcohol use, HBV and HCV infections are more prevalent in HIV-infected patients than those without HIV infection (9) (10) (11) (12) . All-cause mortality was also higher in HIV-infected patients with HBV and/or HCV coinfection(s) than in those with HIV only, although ART has generally increased life expectancy of HIV-infected patients (13) . Nevertheless, little is known about the impact of ART on the development and progression of liver diseases among people living with HIV and AIDS (PLWHA) in China. In a recently published study, Li et al. examined progression of liver fibrosis among ART receiving HIV-infected patients, and found that ART was associated with reduction in liver fibrosis scores in the majority of HIV-hepatitis co-infected and HIV-monoinfected Chinese participants (14) . Unfortunately, this study had only a 48 weeks observation period and did not allow for long-term evaluation of progression of liver fibrosis among HIV patients with ART. Given that Chinese PLWHA are now living much longer owing to life-long ART and are at high risk of non-AIDS deaths particularly liver diseases (15) (16) (17) , research to solicit long-term effects of ART on the development and the outcome of liver diseases especially liver fibrosis is urgently needed.
Liver biopsy is the gold standard technique for diagnosis of liver fibrosis, but it is an invasive procedure and does carry a small risk for complications (18) . Thus, there is a need for a noninvasive method to assess liver fibrosis for monitoring liver disease progression and for pursuing epidemiological analysis. Fibrosis-4 (FIB-4) index has been developed and validated as an inexpensive and accurate noninvasive marker for liver fibrosis in HIV-infected patients (19) (20) (21) , and is increasingly used for studying hepatic fibrosis in HIVinfected patients (14, (22) (23) .
In this retrospective cohort study, we proposed to assess the long-term impact of ART on liver fibrosis measured by FIB-4 index among HIV-infected patients in a rural prefecture of Eastern China.
Materials and Methods

Study design and subject selection
This was a retrospective cohort study of HIV-infected patients receiving ART in Taizhou prefecture of Zhejiang province, Eastern China. To be eligible for the study, participants must fulfill the following selection criteria: i) were sexually infected with HIV, ii) started ART during January 2009 through December 2015, iii) aged ≥ 18 years at ART initiation, iv) had CD4 cell count prior to ART initiation, and v) had available information of age, platelet (PLT) count, alanine transaminase (ALT) and aspartate transaminase (AST) levels for calculation of FIB-4 index at both ART initiation and at least one follow-up visit.
For all participants, the observation period was from the date of ART initiation (i.e. baseline) to December 31, 2016. According to China National Guidelines for Free Antiretroviral Treatment for HIV/AIDS, the first line treatment regimen comprises 2 nucleotide reverse transcriptase inhibitors (NRTIs) plus 1 non-nucleotide reverse transcriptase inhibitors (NNRTI). Most commonly, the 2 NRTIs are either zidovudine (AZT) or stavudine (d4T, replaced by tenofovir disoproxil fumarate (TDF) since 2010) and either lamivudine (3TC) or didanosine (DDI) (stopped in 2008), and the 1 NNRTI is either nevirapine (NVP) or efavirenz (EFV).
This study was approved by the Institutional Review Board (IRB) of the Chinese National Center for AIDS/ STD Control and Prevention and the IRB of Fudan University, Shanghai, China.
Data collection
Demographical, epidemiological and clinical data were extracted from the China AIDS Comprehensive Response Information Management System (CRIMS) which is a unified web-based national information system. All eligible participants were tested for HBsAg and anti-HCV antibody (HCVAb) using enzyme linked immunoabsorbent assay (ELISA) (Kehua Biotechnology Co. Ltd., Shanghai, China). Patients with CD4 cell count decreased from baseline more than 30% were defined as being decreased in CD4 cell count and with increased from baseline higher than 30% were defined as increased in CD4+ (24).
Study outcomes
Liver fibrosis was determined by FIB-4 score, using Sterling's formula calculated as (age [years] (19) . FIB-4 was ranked into 3 classes according to standard cutoff values: < 1.45 for class 1 (no significant fibrosis); 1.45-3.25 for class 2 (moderate fibrosis) and > 3.25 for class 3 (severe fibrosis) (25) . Improvement of liver fibrosis was defined as having > 30% decrease in FIB-4 from baseline, whereas progression of liver fibrosis was defined as having > 30% increase in FIB-4 score from baseline (26-27).
Statistical analysis
All statistical analyses were performed using SPSS version 22 
. Sociodemographic characteristics and CD4 cell count
A total of 955 HIV-infected patients participated in the study. Of them, 75.2% were male, 75.1% were married, 69.2% were HIV-infected through heterosexual transmission and 30.8% through homosexual transmission. The median age of the study participants was 37.0 years, and the median CD4 cell count was 211 cells/μL (Table 1) .
HBV and HCV coinfection
As shown in Table 1 , 125 participants (13.1%) were seropositive for HBsAg and 29 (3.0%) were seropositive for HCVAb. Seven patients (0.7%) were seropositive for both HBsAg and HCVAb. The proportion of HIV monoinfection, HIV/HBV coinfection, HIV/HCV in FIB-4 index) or progression (> 30% increase in FIB-4 index) of liver fibrosis after ART, respectively. For each of the two logistic regression models, independent variables were selected based on existing knowledge of potential causal relationships between risk factors and liver fibrosis. In this regard, variables of appropriate baseline and follow-up characteristics such as demographic variables, HIV transmission mode, HBV and HCV coinfection status, ART regimen and duration as well as CD4 cell count were subject to univariate logistic regression analysis and were included in the final multiple logistic regression models using the "forced entry" criteria for variable selection. A p-value < 0.05 was chosen as the significance level. 
Results
Baseline characteristics
Antiretroviral therapy
As shown in Table 1 , 92.5% of the participants were prescribed with AZT+3TC+EFV/NVP while the other 7.5% were prescribed with TDF+3TC+EFV/NVP. The combination use of TDF+3TC, both of which are efficacious for HBV suppression, was more prevalent among HIV/HBV co-infected participants (15.2%, or 19/125) than among HIV mono-infected participants (6.4%, or 53/830) (χ 2 = 12.11, p < 0.001). About 23% of the participants had received ART for less than three months, whereas 52.7% had received ART for more than one year (Table 1 ).
Follow-up characteristics
CD4 cell count
After antiretroviral therapy, 63.8% of the participants had > 30% increases in CD4 cell count or CD4 cell recovery, whereas 4.5% had > 30% decreases in CD4 cell count. CD4 cell count remained constant from the baseline to the last follow-up after ART among 31.7% of the participants (Table 1 ).
FIB-4 index or liver fibrosis
After antiretroviral therapy, 354 participants (37.1%) had > 30% decreases in FIB-4 index (i.e., improvement of liver fibrosis), 141 (14.8%) had > 30% increases in FIB-4 index (i.e., progression of liver fibrosis), while the remaining 460 participants (48.2%) had stabilized FIB-4 index. As shown in Table 1 , The FIB-4 changing status after ART was significantly associated with the participant's baseline FIB-4 score but not significantly associated with other baseline characteristics. Participants with different CD4 cell count changing status also showed different FIB-4 changing status after ART, with a higher proportion of FIB-4 increase observed among those with decreased CD4 cell count (Table 1) .
Predictors for improvement of liver fibrosis after ART
According to univariate logistic regression analysis, improvement of liver fibrosis after ART was significantly associated with baseline FIB-4 index, duration of ART and CD4 cell count changing status ( 
Predictors for progression of liver fibrosis after ART
According to univariate logistic regression analysis, progression of liver fibrosis after ART was significantly associated with gender and HIV transmission mode, and baseline FIB-4 index (Table 3) . After adjusted for potential confounding effects of the other variables using multiple logistic regression model, progression of liver fibrosis after ART was positively associated with an older age (aOR 
Discussion
This study, to the best of our knowledge, is the first community-based longitudinal cohort study to assess impact of ART on liver fibrosis among HIV-infected patients in Eastern China. We observed that one-third of the HIV-infected patients were living with liver fibrosis before ART and the majority of them had attenuated or stabilized liver fibrosis after ART. In a multicenter cross-sectional study of HIV-positive ARTnaïve patients across twelve provinces in China, the proportion of participants with liver fibrosis or FIB-4 ≥ 1.45 was 26.2% (12 Unchanged (within ± 30%) Increased > 30% Decreased > 30%
Crude OR (95% CI) 
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BioScience Trends Advance Publication P6 a rural prefecture of Yunnan province in Southwestern China (28) . Obviously, these studies observed varied prevalence of liver fibrosis among HIV patients, which are mostly attributable to different sources and characteristics of the study participants. Nevertheless, all the aforementioned studies including the present study reported that liver fibrosis was more prevalent among patients with HBV and/or HCV coinfection than those with HIV monoinfection, which is also consistent with findings from other countries (22, (29) (30) (31) .
The existing literature extensively evaluates liver disease progression among HIV/HCV or HIV/ HBV coinfected patients receiving ART (27, (32) (33) , with only a few studies examining liver disease progression and potential risk factors among HIVmonoinfected patients. In the present study, we found that a substantial proportion of HIV-infected patients, regardless of HBV and/or HCV coinfection status, had remarkable reduction or improvement of liver fibrosis after ART, further corroborating long-term benefits of ART on liver diseases in Chinese HIV patients (28) . Such improvement of liver fibrosis was significantly associated with age, baseline FIB-4 score and post-ART CD4 cell recovery. It is by definition that patients with higher baseline FIB-4 score had more chances to present a reduced FIB-4 score after ART while having less chances to present an increased FIB-4 score during the follow-up, as long as ART had beneficiary effects on liver fibrosis. In this study, HIV patients aged over 45 years were less likely to gain improvement of liver fibrosis than younger patients. This is not surprise given that the development of liver cirrhosis is generally a slow disease progression and takes over 20-30 years. In fact, a study of HBV infected patients in China revealed that the protective effect of female gender against hepatic cirrhosis gradually lost with increasing age (34) . Therefore, the less improvement of liver fibrosis among the elders underscores the importance of more closely monitoring and intervening liver disease progression in HIV-infected elderly people. Furthermore, the significant association between increased CD4 cell count and improved liver fibrosis after ART observed by the present study as well as studies in China and other countries further indicates the importance of promotion of CD4 cell recovery and maintenance of normal immune status through combination antiretroviral therapy (cART) for HIV patients (23, 35) . Since early initiation of cART remarkably improves CD4 cell recovery and generally slows down the disease progression (14, (36) (37) (38) , it is highly recommended that HIV-infected patients should get treated soonest possible after HIV diagnosis.
On the other hand, about 14.8% of the HIV patients had development or progression of liver fibrosis during ART. In fact, rapid fibrosis development from ART as well as from the chronic HIV infection itself is of serious concern to HIV patients (28,39-41 ). The pathophysiology of liver fibrosis in patients with HIV is a multifactorial process whereby chronic immune activation and inflammation that are unable to be fully suppressed by ART promote production of liver fibrosis. In addition, mitochondrial toxicity, triggered by both ART and HIV, contributes to intrahepatic damage, which is even more severe in patients coinfected with viral hepatitis (42) .
More progression of liver fibrosis was observed among the elders. As mentioned above, HIV patients suffered more and rapid progression in various chronic diseases including liver fibrosis as they are getting old. In the meantime, we also found that female gender was a protective predictor of liver fibrosis progression among treated HIV patients, especially compared with heterosexual men. This is consistent with observations among both HIV-infected and HIV-uninfected populations (34, 43) . Although this is most likely due to pathophysiological differences and differential responses to ART between males and females (44) (45) (46) , the less exposure of female patients to behaviors that favorite liver disease progression such as smoking and drinking cannot be ruled out (10, (47) (48) . Interestingly, we found that homosexual men or men who have sex with men (MSM) were less likely to encounter liver fibrosis progression than heterosexual men. The mechanisms are unknown and remain to be defined.
This study has a couple of limitations. First, misclassification of liver fibrosis is unavoidable when a noninvasive marker instead of liver biopsy was used to define liver fibrosis. However, the misclassification should be non-differential and in turn made the association estimates biased to be more conservative. Moreover, liver biopsy was not feasible in this large epidemiologic study. Second, life style data including alcohol use and physical exercise that have potential impacts on liver diseases were not collected in this study, further limiting our capacity to draw a powerful causal inference.
Despite the limitations, this large longitudinal study has several important clinical and public health implication. First, improvement of liver fibrosis is achievable among HIV patients with better CD4 cell recovery which can be expectable through early initiation of ART. Second, liver fibrosis and hepatotoxicity associated with ART should be monitored as early as possible and throughout till the end of treatment, with special attention to the elderly and heterosexual men.
